Advamed Payment Alert: Breakthrough Pathway Payment for Medical Devices
August 9, 2019
level to 65 percent.
These changes represent significant wins for coverage and payment of innovative medical devices and are the latest in a series of payment policy victories that are the result of our multi-year advocacy efforts.
Key highlights of the final rule include the following:
- Alternative NTAP Pathway for Breakthrough Devices and QIDPs
- Change to the Calculation of the NTAP Payment Amount
- Clarifications to the Substantial Clinical Improvement Criterion
- New Technology Add-On Payments (NTAPs) Applications
- Antimicrobial Resistance Diagnoses as Complications and Comorbidities
- Payment Rate Update
Read the Press Release/Fact Sheet.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
